Understanding Immunity in Children Vaccinated With Live Attenuated Influenza Vaccine | Zendy

Ian Shan | Zendy; Chantelle L. White | Zendy; Jennifer L. Nayak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Understanding Immunity in Children Vaccinated With Live Attenuated Influenza Vaccine

Author(s) -

Ian Shan,

Chantelle L. White,

Jennifer L. Nayak

Publication year - 2019

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piz083

Subject(s) - live attenuated influenza vaccine , medicine , vaccination , immunity , immunology , immune system , nasal administration , virology , attenuated vaccine , influenza vaccine , biology , virulence , biochemistry , gene

Live attenuated influenza vaccine (LAIV), or FluMist, was approved for use in the United States in 2003. This vaccine, administered intranasally, offers the advantage of stimulating immunity at the site of infection in the upper respiratory tract and, by mimicking natural infection, has the potential to elicit a multifaceted immune response. However, the development of immunity following LAIV administration requires viral replication, causing vaccine effectiveness to be impacted by both the replicative fitness of the attenuated viruses being administered and the degree of the host’s preexisting immunity. In this review, we discuss the current state of knowledge regarding the mechanisms of protection elicited by LAIV in children, contrast this with immune protection that develops upon vaccination with inactivated influenza vaccines, and briefly discuss both the potential advantages as well as challenges offered by this vaccination platform.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research